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Introduction
Prostate cancer is prevalent throughout the world. It is 
the most common cancer in European men and the second 
most common in American men [1]. In the United States, 
prostate cancer presents a signifi cant health challenge; 
each year, 200,000 new cases are reported and 32,000 
men die of the disease [2]. Historically, there has been a 
shift toward early stage diagnosis of prostate tumors 
using the prostate­specifi c antigen test. Th is test was 
intended to enable earlier treatment of patients and a 
better outcome. However, prostate cancer frequently 
meta stasizes or recurs, even after early treatment [3]. In 
addition, owing to limitations associated with the 
prostate­specifi c antigen test, its use is controversial and 
in many instances no longer recommended [4].
Th e current standard therapy for patients with meta­
static or recurrent prostate cancer involves the reduction 
of androgen levels [1]. Under this androgen­deprivation 
therapy, tumor progression can be stopped for several 
years, but eventually disease progression resumes, albeit 
more slowly. Th is castration­resistant prostate cancer 
(CRPC) is notoriously heterogeneous in terms of 
res ponse to treatment and patient survival [1]. Th erefore, 
a better understanding of the disease and its response to 
treatments is urgently required.
Challenges in prostate tumor analysis
Studying tumor tissue from patients with metastatic 
prostate cancer is challenging, as it tends to spread to the 
bone, making biopsies diffi  cult. Even the primary tumors 
themselves are small and mixed in with stromal tissue, 
and so precise dissection is challenging [5]. Despite these 
obstacles, researchers have undertaken whole­exome and 
whole­genome sequencing studies of CRPC cases in an 
eff ort to reveal the genetics changes in these patients 
[5,6]. Studies such as these found no single gene mutated 
across all prostate cancers, but did fi nd alterations such 
as the fusion (TMPRSS2-ERG) between the trans mem­
brane protease, serine 2 gene (TMPRSS2) and the ETS 
related gene (ERG) in about half of the tumors [6]. 
Additionally, low overall somatic point mutation rates 
were consistently observed when compared with other 
tumors such as glioblastomas [5,6].
Because acquiring tumor tissue is problematic, other 
approaches are needed. One such approach, blood­based 
assays, off ers distinct advantages. Th ese assays are only 
minimally invasive, do not require intricate dissections 
and are, therefore, more straightforward in their stan­
dardi zation, allowing for repeated sampling over time. 
Studies using whole blood have shown that mRNA 
expression signatures can be used to group patients with 
CRPC into high­ and low­risk groups [7]. Circulating 
tumor cells (CTCs) are rare in the peripheral blood of 
patients with cancer, including those with metastatic 
prostate cancer [8]. Th ese cells have been isolated and 
used to identify molecular markers of prostate cancer, as 
well as its response to treatments [8]. While informative, 
these studies are limited by their reliance on the isolation 
of CTCs through the expression of epithelial cell 
adhesion molecule [8]. Th erefore, this technique requires 
additional expenses involving reagents and equipment 
beyond just a simple blood draw [8]. In addition, any 
CTCs that are epithelial cell adhesion molecule­negative 
will be missed by this assay.
Abstract
Personalized genomics will only be useful for 
monitoring the prognosis of patients with cancer when 
it becomes much more cost-eﬀ ective and quicker to 
apply. A recent study brings this closer to reality with 
the development of plasma-seq, a rapid, low-cost 
method that sequences the circulating DNA present 
in the peripheral blood of patients with cancer. The 
power of this technique is demonstrated with the 
examination of tumor genomes from patients with 
prostate cancer.
© 2010 BioMed Central Ltd
Plasma-seq: a novel strategy for metastatic 
prostate cancer analysis
Caitlin Farris and Jeﬀ rey M Trimarchi*
See related research article: http://genomemedicine.com/content/5/4/30
R E S E A R C H  H I G H L I G H T
*Correspondence: jtrimarc@iastate.edu
Department of Genetics, Development and Cell Biology, 2114 Molecular Biology, 
Iowa State University, Ames, IA 50011, USA
Farris and Trimarchi Genome Medicine 2013, 5:35 
http://genomemedicine.com/content/5/4/35
© 2013 BioMed Central Ltd
Fragments of circulating tumor DNA (ctDNA), 
140  base pairs (bp) to 170  bp long, have been found at 
low numbers in the blood of patients with tumors [9]. 
Analysis of this plasma DNA provides a new option for 
the analysis of tumor genomes. It can be used to identify 
recurring mutations in subsets of patients with cancer. 
Previously, ctDNA from ovarian cancer has been ampli­
fied and sequenced using a tagged amplicon method 
called TAm­seq [9]. This technique had excellent sensi­
tivity as demonstrated by its ability to sequence DNA 
regions present in a single copy of ctDNA [9]. Altogether, 
this ‘liquid biopsy’ approach shows great potential and, 
with standardization and a reduction in price, could 
revolutionize personal genomics in cancer management.
Plasma-seq
To bring the power of whole­genome analysis to a more 
routine clinical benchtop setting, Heitzer et al. [10] have 
now developed an improved technique that profiles cell­
free plasma DNA from patients (Figure  1). This new 
method, which the authors name plasma­seq, uses shallow 
sequencing (depth of about 0.1×) with a benchtop high­
throughput instrument (Illumina MiSeq; Illumina, Inc., 
San Diego, CA, USA) to examine the tumor genomes of 
patients with metastasized prostate cancer. Before imple­
menting plasma­seq on samples from these patients, 
Heitzer et al. thoroughly tested their approach on differ­
ent samples, including fragmented DNA from a colon 
cancer cell line and samples from pregnancies with 
trisomies of distinct chromosomes. Plasma­seq was con­
sis tently able to identify the extra chromosome segments 
in the trisomy cases, demonstrating the robustness of this 
technique.
The authors then progressed to whole­genome sequen­
cing of plasma samples from individuals without cancer 
and those with cancer. These experiments revealed many 
copy number differences that were previously associated 
with prostate cancer. Among these changes were the 
TMPRSS2-ERG fusion, losses of chromosome 8p, gains 
of chromosome 8q, and gains of the androgen receptor. 
All of this information was obtained at a very reasonable 
cost and in only two days. To further demonstrate the 
effectiveness of plasma­seq, serial plasma analyses were 
performed on two patients. Of these, one patient had 
their primary tumor completely removed 13 years prior 
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Figure 1. An overview of plasma-seq. Blood is drawn from the 
patient, plasma prepared and the plasma DNA is isolated. The 
shotgun library is then prepared for sequencing. This step takes a 
total of 24 hours to perform. Shallow sequencing of the plasma DNA 
using an Illumina MiSeq machine takes about 12 hours to perform. 
Finally, alignment of the DNA sequences and analysis of the resulting 
data take between 2 and 3 hours. bp, base pair; ctDNA, circulating 
tumor DNA.
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to the plasma analyses. Because the primary tumor was 
predicted to be heterogeneous, it was divided into six 
sections and whole­genome sequencing was performed 
for each region. Consistent with the prediction, whole­
genome sequencing revealed different copy number 
changes in different regions. Plasma samples were taken 
three different times over a 9­month period, 13  years 
after tumor resection to analyze secondary tumors in a 
castration resistant patient. Plasma­seq identified 
multiple chromosomal rearrangements that had not been 
present in the original primary tumor. Additionally, the 
results at each of the three distinct time points were 
virtually the same, suggesting that one dominant clone 
released DNA into circulation. These results demonstrate 
the utility of plasma­seq not only for prostate cancer, but 
also in tracking changes in any metastatic cancer.
Conclusions
This is the first whole­genome sequencing analysis from 
plasma DNA of patients with prostate cancer. Heitzer et 
al. showed that analysis of plasma DNA from a patient 
could be used as a noninvasive method of tumor cell 
genotyping that can be repeated over time and used to 
monitor tumor responsiveness to therapy. The authors 
show that plasma­seq is both reliable and robust through 
various controls and comparisons with other methods. 
Plasma­seq is faster and cheaper than previously used 
protocols, while still being reliable, making it more 
advantageous for use in a clinical setting. It also requires 
less specialized equipment than what is normally 
required for circulating tumor cell analysis. One dis­
advantage of plasma­seq is that the limited coverage 
makes structural chromosomal rearrangements difficult 
to identify with high confidence. It also has a reduced 
resolution for the identification of mutants. This suggests 
that it is excellent for finding previously identified muta­
tions, but perhaps not as useful for the identification of 
new mutations involved in prostate cancer metastasis. 
Given its dramatically reduced cost and time of analysis, 
plasma­seq will undoubtedly be more widely applied in 
different clinical settings in the near future.
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